HC Wainwright Reiterates “Buy” Rating for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $80.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 288.92% from the company’s current price. HC Wainwright also issued estimates for Celldex Therapeutics’ Q1 2025 earnings at ($0.73) EPS.

Several other research firms have also commented on CLDX. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. UBS Group began coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $44.00 price objective for the company. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $56.50.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX opened at $20.57 on Friday. Celldex Therapeutics has a one year low of $19.83 and a one year high of $53.18. The firm has a market cap of $1.36 billion, a P/E ratio of -8.00 and a beta of 1.60. The firm has a 50-day simple moving average of $23.86 and a 200-day simple moving average of $28.92.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The business had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. On average, research analysts predict that Celldex Therapeutics will post -2.48 EPS for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Several large investors have recently bought and sold shares of the stock. KBC Group NV grew its position in Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares during the last quarter. Invesco Ltd. grew its position in Celldex Therapeutics by 2.1% during the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company’s stock worth $1,064,000 after purchasing an additional 871 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 878 shares during the last quarter. Swiss National Bank grew its position in Celldex Therapeutics by 1.2% during the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company’s stock worth $2,964,000 after purchasing an additional 1,400 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its position in Celldex Therapeutics by 5.1% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock worth $1,449,000 after purchasing an additional 2,070 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.